Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential estimation of 95% effective intranasal esketamine dose with oral midazolam for pediatric dental caries examination
ChiCTR2200058047Phase 4Recruiting
- Sponsor
- The Affiliated Stomatological Hospital of Chongqing Medical University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of esketamine and midazolam in Dental anxiety, sponsored by The Affiliated Stomatological Hospital of Chongqing Medical University. Primary endpoint: 95% effective dose of intranasal esketamine (ED95) in combination with oral midazolam 0.5 mg/kg. Started Apr 2022; status: recruiting.
02
Drugs
esketaminemidazolam
03
Conditions
Dental anxiety
Beyond the preview
Go deeper on ChiCTR2200058047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058047.